Influenza Viral Challenge Study of CC-42344 in Healthy Participants

• Status: Recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus. Participants will not know whether they are getting placebo or CC-42344. The amount of virus in nasal samples will be measured over time. Side effects and pharmacokinetics (the amount of CC-42344 in blood) will also be measured.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cocrystal Pharma, Inc.
• Collaborator: hVIVO Services Limited

Criteria

Inclusion Criteria:

• Healthy adults

• Body weight ≥50 kg

• Body mass index ≥18 kg/m2 and ≤35 kg/m2

• Serology results consistent with susceptibility to challenge virus infection

Exclusion Criteria:

• History of or current significant medical condition

• Upper or lower respiratory tract infection within 4 weeks

• Vaccination within 4 weeks